Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Gene HRAS
Variant G13R
Impact List missense
Protein Effect loss of function - predicted
Gene Variant Descriptions HRAS G13R is hotspot mutation that lies within the GTP binding domain of the Hras protein (UniProt.org). G13R results in activation of Mapk and Pi3k signaling, increased cell proliferation in culture (PMID: 22683711), and is predicted to lead to a loss of Hras protein function based on the effects of other HRAS G13 mutations.
Associated Drug Resistance
Category Variants Paths

HRAS mutant HRAS G13X HRAS G13R

HRAS mutant HRAS act mut HRAS G13R

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_005343.4
gDNA chr11:g.534286C>G
cDNA c.37G>C
Protein p.G13R
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_176795.5 chr11:g.534286C>G c.37G>C p.G13R RefSeq GRCh38/hg38
NM_005343 chr11:g.534286C>G c.37G>C p.G13R RefSeq GRCh38/hg38
NM_001130442 chr11:g.534286C>G c.37G>C p.G13R RefSeq GRCh38/hg38
NM_001130442.3 chr11:g.534286C>G c.37G>C p.G13R RefSeq GRCh38/hg38
NM_005343.3 chr11:g.534286C>G c.37G>C p.G13R RefSeq GRCh38/hg38
NM_176795 chr11:g.534286C>G c.37G>C p.G13R RefSeq GRCh38/hg38
NM_005343.4 chr11:g.534286C>G c.37G>C p.G13R RefSeq GRCh38/hg38
NM_001130442.2 chr11:g.534286C>G c.37G>C p.G13R RefSeq GRCh38/hg38
NM_176795.4 chr11:g.534286C>G c.37G>C p.G13R RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
HRAS G13R PTEN inact mut Advanced Solid Tumor predicted - sensitive AZD8186 + Tipifarnib Preclinical - Cell culture Actionable In a preclinical study, cultured cells expressing HRAS G13R and PTEN inactivating mutations in the context of an HRAS, NRAS, and KRAS knockout were sensitive to combined treatment with Zarnestra (tipifarnib) and AZD8186 (Cancer Res 2022;82(12_Suppl):Abstract nr 1181). detail...
HRAS G13R PTEN inact mut Advanced Solid Tumor predicted - sensitive Tipifarnib Preclinical - Cell culture Actionable In a preclinical study, cultured cells expressing HRAS G13R and PTEN inactivating mutations in the context of an HRAS, NRAS, and KRAS knockout were resistant to treatment with Zarnestra (tipifarnib) (Cancer Res 2022;82(12_Suppl):Abstract nr 1181). detail...
ALK F1245Y HRAS G13R neuroblastoma predicted - resistant Lorlatinib Case Reports/Case Series Actionable In a Phase I trial, a neuroblastoma patient harboring ALK F1245Y developed progressive disease on treatment with Lorbrena (lorlatinib) and was found to have acquired HRAS G13R via circulating tumor DNA (PMID: 37147298; NCT03107988). 37147298